Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer—A New Diagnostic and Therapeutic Target?

Several studies have demonstrated an expression of the prostate-specific membrane antigen (PSMA) in the cancer-related neovasculature of thyroid malignancies. Due to the poor prognosis and limited therapeutic options for patients with anaplastic (ATC) and poorly differentiated (PDTC) thyroid carcino...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sabine Wächter, Pietro Di Fazio, Elisabeth Maurer, Jerena Manoharan, Corinna Keber, Andreas Pfestroff, Damiano Librizzi, Detlef K. Bartsch, Markus Luster, Friederike Eilsberger
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	anaplastic thyroid carcinoma poorly differentiated thyroid carcinoma prostate-specific membrane antigen theranostic neovasculature immunohistochemistry Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/9e1c2bdd96834eab9765d9c931a04e75
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9e1c2bdd96834eab9765d9c931a04e75
record_format	dspace
spelling	oai:doaj.org-article:9e1c2bdd96834eab9765d9c931a04e752021-11-25T17:02:40ZProstate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer—A New Diagnostic and Therapeutic Target?10.3390/cancers132256882072-6694https://doaj.org/article/9e1c2bdd96834eab9765d9c931a04e752021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5688https://doaj.org/toc/2072-6694Several studies have demonstrated an expression of the prostate-specific membrane antigen (PSMA) in the cancer-related neovasculature of thyroid malignancies. Due to the poor prognosis and limited therapeutic options for patients with anaplastic (ATC) and poorly differentiated (PDTC) thyroid carcinoma, the aim of our study was to investigate the theranostic approach of PSMA expression in these patients. The PSMA uptake on Gallium-68 (<sup>68</sup>Ga)-PSMA-positron emission tomography/computed tomography (PET/CT) and glucose uptake on F-18-Fluordeoxyglucose (<sup>18</sup>F-FDG)-PET/CTs were analysed in two ATC and six PDTC patients. The PSMA expression in corresponding patients’ tissue samples was detected by immunohistochemistry. In addition, various tissue sections from 22 ATC and six PDTC patients were examined concerning PSMA expression. <sup>68</sup>Ga-PSMA-PET/CT showed heterogeneous PSMA expression among patients and lesions. Six of the eight analyzed patients (two ATC, four PDTC) showed increased glucose metabolism without increased PSMA uptake after PET/CT. In one patient (PDTC), <sup>18</sup>F-FDG-PET/CT tracer uptake was positive and <sup>68</sup>Ga-PSMA-PET/CT showed heterogeneous results. Another patient (PDTC) evidenced only PSMA-positive lesions and received two cycles of Lutetium-177 (<sup>177</sup>Lu)-PSMA therapy, which kept his disease stable for seven months. There was a correlation between immunohistochemical PSMA expression and uptake on <sup>68</sup>Ga-PMSA-PET/CT in three of the examined patients. Twenty-seven of the analyzed 39 ATC and 13 of the analyzed 22 PDTC tissue sections showed a strong PSMA expression. Considering the rarity of PDTC and ATC, which is the reason for the small patient population we studied, the findings of this study confirm the high diagnostic sensitivity and superiority of <sup>18</sup>F-FDG-PET/CT in comparison to <sup>68</sup>Ga-PSMA-PET/CT in the diagnosis of ATC and PDTC. However, it can be suggested that <sup>68</sup>Ga-PMSA-PET/CT can be considered as a beneficial adjunct to the well-established <sup>18</sup>F-FDG-PET/CT for a few individual selected patients with ATC and PDTC to detect lesions not discovered by <sup>18</sup>F-FDG-PET/CT and to determine patients’ eligibility for a radioligand therapy. Radiolabelled PSMA-ligands may, in the future, represent a theranostic approach with only minor side effects for a few individual selected patients with ATC and PDTC who need alternative treatment options in case of progression when established therapies are no longer effective. However, due to the small sample size of our collective, larger studies are needed to allow for a final evaluation on the significance of PSMA-targeted diagnostic and therapy for ATC and PDTC.Sabine WächterPietro Di FazioElisabeth MaurerJerena ManoharanCorinna KeberAndreas PfestroffDamiano LibrizziDetlef K. BartschMarkus LusterFriederike EilsbergerMDPI AGarticleanaplastic thyroid carcinomapoorly differentiated thyroid carcinomaprostate-specific membrane antigentheranosticneovasculatureimmunohistochemistryNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5688, p 5688 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	anaplastic thyroid carcinoma poorly differentiated thyroid carcinoma prostate-specific membrane antigen theranostic neovasculature immunohistochemistry Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	anaplastic thyroid carcinoma poorly differentiated thyroid carcinoma prostate-specific membrane antigen theranostic neovasculature immunohistochemistry Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sabine Wächter Pietro Di Fazio Elisabeth Maurer Jerena Manoharan Corinna Keber Andreas Pfestroff Damiano Librizzi Detlef K. Bartsch Markus Luster Friederike Eilsberger Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer—A New Diagnostic and Therapeutic Target?
description	Several studies have demonstrated an expression of the prostate-specific membrane antigen (PSMA) in the cancer-related neovasculature of thyroid malignancies. Due to the poor prognosis and limited therapeutic options for patients with anaplastic (ATC) and poorly differentiated (PDTC) thyroid carcinoma, the aim of our study was to investigate the theranostic approach of PSMA expression in these patients. The PSMA uptake on Gallium-68 (<sup>68</sup>Ga)-PSMA-positron emission tomography/computed tomography (PET/CT) and glucose uptake on F-18-Fluordeoxyglucose (<sup>18</sup>F-FDG)-PET/CTs were analysed in two ATC and six PDTC patients. The PSMA expression in corresponding patients’ tissue samples was detected by immunohistochemistry. In addition, various tissue sections from 22 ATC and six PDTC patients were examined concerning PSMA expression. <sup>68</sup>Ga-PSMA-PET/CT showed heterogeneous PSMA expression among patients and lesions. Six of the eight analyzed patients (two ATC, four PDTC) showed increased glucose metabolism without increased PSMA uptake after PET/CT. In one patient (PDTC), <sup>18</sup>F-FDG-PET/CT tracer uptake was positive and <sup>68</sup>Ga-PSMA-PET/CT showed heterogeneous results. Another patient (PDTC) evidenced only PSMA-positive lesions and received two cycles of Lutetium-177 (<sup>177</sup>Lu)-PSMA therapy, which kept his disease stable for seven months. There was a correlation between immunohistochemical PSMA expression and uptake on <sup>68</sup>Ga-PMSA-PET/CT in three of the examined patients. Twenty-seven of the analyzed 39 ATC and 13 of the analyzed 22 PDTC tissue sections showed a strong PSMA expression. Considering the rarity of PDTC and ATC, which is the reason for the small patient population we studied, the findings of this study confirm the high diagnostic sensitivity and superiority of <sup>18</sup>F-FDG-PET/CT in comparison to <sup>68</sup>Ga-PSMA-PET/CT in the diagnosis of ATC and PDTC. However, it can be suggested that <sup>68</sup>Ga-PMSA-PET/CT can be considered as a beneficial adjunct to the well-established <sup>18</sup>F-FDG-PET/CT for a few individual selected patients with ATC and PDTC to detect lesions not discovered by <sup>18</sup>F-FDG-PET/CT and to determine patients’ eligibility for a radioligand therapy. Radiolabelled PSMA-ligands may, in the future, represent a theranostic approach with only minor side effects for a few individual selected patients with ATC and PDTC who need alternative treatment options in case of progression when established therapies are no longer effective. However, due to the small sample size of our collective, larger studies are needed to allow for a final evaluation on the significance of PSMA-targeted diagnostic and therapy for ATC and PDTC.
format	article
author	Sabine Wächter Pietro Di Fazio Elisabeth Maurer Jerena Manoharan Corinna Keber Andreas Pfestroff Damiano Librizzi Detlef K. Bartsch Markus Luster Friederike Eilsberger
author_facet	Sabine Wächter Pietro Di Fazio Elisabeth Maurer Jerena Manoharan Corinna Keber Andreas Pfestroff Damiano Librizzi Detlef K. Bartsch Markus Luster Friederike Eilsberger
author_sort	Sabine Wächter
title	Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer—A New Diagnostic and Therapeutic Target?
title_short	Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer—A New Diagnostic and Therapeutic Target?
title_full	Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer—A New Diagnostic and Therapeutic Target?
title_fullStr	Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer—A New Diagnostic and Therapeutic Target?
title_full_unstemmed	Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer—A New Diagnostic and Therapeutic Target?
title_sort	prostate-specific membrane antigen in anaplastic and poorly differentiated thyroid cancer—a new diagnostic and therapeutic target?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/9e1c2bdd96834eab9765d9c931a04e75
work_keys_str_mv	AT sabinewachter prostatespecificmembraneantigeninanaplasticandpoorlydifferentiatedthyroidcanceranewdiagnosticandtherapeutictarget AT pietrodifazio prostatespecificmembraneantigeninanaplasticandpoorlydifferentiatedthyroidcanceranewdiagnosticandtherapeutictarget AT elisabethmaurer prostatespecificmembraneantigeninanaplasticandpoorlydifferentiatedthyroidcanceranewdiagnosticandtherapeutictarget AT jerenamanoharan prostatespecificmembraneantigeninanaplasticandpoorlydifferentiatedthyroidcanceranewdiagnosticandtherapeutictarget AT corinnakeber prostatespecificmembraneantigeninanaplasticandpoorlydifferentiatedthyroidcanceranewdiagnosticandtherapeutictarget AT andreaspfestroff prostatespecificmembraneantigeninanaplasticandpoorlydifferentiatedthyroidcanceranewdiagnosticandtherapeutictarget AT damianolibrizzi prostatespecificmembraneantigeninanaplasticandpoorlydifferentiatedthyroidcanceranewdiagnosticandtherapeutictarget AT detlefkbartsch prostatespecificmembraneantigeninanaplasticandpoorlydifferentiatedthyroidcanceranewdiagnosticandtherapeutictarget AT markusluster prostatespecificmembraneantigeninanaplasticandpoorlydifferentiatedthyroidcanceranewdiagnosticandtherapeutictarget AT friederikeeilsberger prostatespecificmembraneantigeninanaplasticandpoorlydifferentiatedthyroidcanceranewdiagnosticandtherapeutictarget
_version_	1718412792371871744

Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer—A New Diagnostic and Therapeutic Target?

Ejemplares similares